This review focuses on dosage, mechanism of action, efficacy in real world studies and the key studies to date featuring Brentuximab vedotin. Guiding commentary is supplied by Professor Jeff Szer, Director of the Department of Clinical Haematology & Bone Marrow Transplant Service at Royal Melbourne Hospital, and Director of the Western and Central Melbourne Integrated Cancer Service.
Please login below to download this issue (PDF)